4. Downplaying Dangers to Regulators
Pharmaceutical companies worked diligently to minimize the perceived dangers of opioids in their communications with government regulators. By presenting selective data and underreporting adverse effects, they delayed the implementation of stricter controls and oversight. This strategic approach, as reported by The Guardian, allowed opioid sales to flourish unchecked, further fueling the epidemic before meaningful intervention could take place.
